Comparative Pharmacology
Head-to-head clinical analysis: EMERPHED versus HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMERPHED versus HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
EMERPHED vs HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
One tablet (hydrocodone bitartrate 5 mg/pseudoephedrine HCl 60 mg) orally every 4 to 6 hours as needed for pain and nasal congestion; maximum: 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Hydrocodone terminal elimination half-life is approximately 3.8–4.5 hours in adults. Pseudoephedrine half-life is about 4–6 hours, but may be prolonged to 10–20 hours in patients with acidic urine or renal impairment. The combination product's half-life reflects individual components.
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Hydrocodone is primarily excreted renally as unchanged drug and metabolites (norhydrocodone, hydromorphone, conjugated metabolites); about 26% of a dose is excreted in urine as unchanged hydrocodone and about 25% as norhydrocodone. Pseudoephedrine is predominantly excreted unchanged in urine (55–75%) with the remainder as N-demethylated metabolites; renal excretion is pH-dependent, with acidic urine enhancing elimination. Biliary/fecal excretion is minimal for both components.
Category C
Category A/B
Sympathomimetic
Sympathomimetic